Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 3,004 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dementia Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of the Aliviado DSD Caregiving Mastery Program

NCT05630014
View directory record Official record
Conditions
Delirium Superimposed on Dementia
Interventions
Aliviado DSD Caregiving Mastery Program
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
2
States / cities
New York, New York • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 23, 2026, 5:32 AM EDT
Completed Not applicable Interventional Results available

Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease

NCT00348309
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg, Placebo, Donepezil
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
41
States / cities
Litchfield Park, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 23, 2026, 5:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Aligning Medications With What Matters Most

NCT04938648
View directory record Official record
Conditions
Polypharmacy, Alzheimer Disease and Related Dementias
Interventions
Pharmacist-led deprescribing intervention
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 23, 2026, 5:32 AM EDT
Completed Phase 3 Interventional

Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study

NCT00053599
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Simvastatin
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2009 · Synced Oct 23, 2026, 5:32 AM EDT
Terminated Phase 3 Interventional Results available

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT04408755
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
45
States / cities
Fort Smith, Arkansas • La Jolla, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 23, 2026, 5:32 AM EDT
Recruiting Not applicable Interventional

Early Age-Related Hearing Loss Investigation (EARHLI)

NCT06174038
View directory record Official record
Conditions
Alzheimer Disease, Hearing Loss, Cognitive Impairment
Interventions
Hearing Intervention, Health Education Intervention
Device · Behavioral
Lead sponsor
Columbia University
Other
Eligibility
55 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 23, 2026, 5:32 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Caring Relationships Expression Study

NCT05627687
View directory record Official record
Conditions
Caregiver Burden, Anxiety, Stress
Interventions
Heart Rate Variability Biofeedback, Music Listening Control
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 12, 2024 · Synced Oct 23, 2026, 5:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of 18F-AV-45 in Healthy Volunteers

NCT01564706
View directory record Official record
Conditions
Alzheimer Disease
Interventions
florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Jenkintown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2012 · Synced Oct 23, 2026, 5:32 AM EDT
Enrolling by invitation No phase listed Observational

Feasibility of Lecanemab Registry and Clinical Outcome Measures

NCT06285448
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Lecanemab
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 23, 2026, 5:32 AM EDT
Recruiting Not applicable Interventional

Neurologic Stem Cell Treatment Study

NCT02795052
View directory record Official record
Conditions
Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
Interventions
Intravenous and Intranasal BMSC
Procedure
Lead sponsor
MD Stem Cells
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Westport, Connecticut • Coral Springs, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 23, 2026, 5:32 AM EDT
Enrolling by invitation Not applicable Interventional

Cognitive-Behavioral Therapy for Irritability in Children With Autism Spectrum Disorder and Intellectual Disability

NCT02914951
View directory record Official record
Conditions
Autism, Intellectual Disability
Interventions
Cognitive-Behavioral Therapy, Functional magnetic resonance imaging (fMRI)
Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
8 Years to 16 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 23, 2026, 5:32 AM EDT
Terminated Phase 4 Interventional Results available

Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia.

NCT01825577
View directory record Official record
Conditions
Dementia, Accidental Falls, Apathy
Interventions
Transdermal Methylphenidate
Drug
Lead sponsor
St. Louis University
Other
Eligibility
65 Years to 95 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 23, 2026, 5:32 AM EDT
Completed Not applicable Interventional

Advance Care Planning in Cognitive Disorders Clinic

NCT03864965
View directory record Official record
Conditions
Advance Care Planning
Interventions
Advance Care Planning
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 23, 2026, 5:32 AM EDT
Not listed Phase 4 Interventional

Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

NCT06093451
View directory record Official record
Conditions
Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
Interventions
Dexmedetomidine, Lorazepam 2 MG/ML
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 23, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.

NCT01436045
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Insulin glulisine, Saline
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
65 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 23, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Results available

Apathy in Dementia Methylphenidate Trial 2

NCT02346201
View directory record Official record
Conditions
Apathy, Alzheimer's Disease
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Little Rock, Arkansas • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 23, 2026, 5:32 AM EDT
Completed Not applicable Interventional

Behavioral Interventions to Prevent or Delay Dementia

NCT02265757
View directory record Official record
Conditions
Mild Cognitive Impairment, Memory Disorders, Mild Dementia, Impaired Cognition, Mild Cognitive Disorder, Amnestic Disorder, Dementia and Amnestic Conditions, Poor Short-term Memory, Memory Impairment
Interventions
Cognitive Rehabilitation, Computer Brain Fitness Training, Support Group (patient and partner), Wellness Education, Physical Exercise
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years and older
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 23, 2026, 5:32 AM EDT
Not listed Not applicable Interventional

NRC:Improving Healthcare for Cognitively Impaired Elders and Their Caregivers

NCT03289377
View directory record Official record
Conditions
Alzheimer Disease, Nurse Training
Interventions
RDAD Training
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 23, 2026, 5:32 AM EDT
Completed Not applicable Interventional Results available

Dementia Symptom Management at Home Program

NCT03255967
View directory record Official record
Conditions
Dementia
Interventions
DSM-H, Standard of Care
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
65 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 23, 2026, 5:32 AM EDT
Completed Phase 1 Interventional

Patients With ALS and Other Motor Disorders Will be Treated With Umbilical or Placental Mesenchymal Cell Exosome Solution

NCT07105371
View directory record Official record
Conditions
Motor Disorders
Interventions
Exosome Secretome
Biological
Lead sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Naples, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 5:32 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Telehealth in Lewy Body Dementia

NCT05014971
View directory record Official record
Conditions
Lewy Body Dementia With Behavioral Disturbance, Lewy Body Parkinson Disease, Lewy Body Disease
Interventions
Tele-neurohub
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 23, 2026, 5:32 AM EDT
Recruiting Not applicable Interventional

Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study

NCT02740634
View directory record Official record
Conditions
Atypical Alzheimer's Disease, Logopenic Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA), Alzheimer Disease, Alzheimer Disease, Early Onset, Amnestic Disorder, Amnestic Symptoms, Amnestic Mild Cognitive Disorder
Interventions
F-18 AV 1451, C-11 PiB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 23, 2026, 5:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI

NCT00483028
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
donezepil (Aricept)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 90 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
2
States / cities
New Haven, Connecticut • Albany, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2008 · Synced Oct 23, 2026, 5:32 AM EDT
Terminated Phase 3 Interventional Results available

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

NCT05026177
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Simufilam, Placebo
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
50 Years to 87 Years
Enrollment
1,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
65
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 23, 2026, 5:32 AM EDT